Uppsala

• A multi-centre, randomised, single-blind Phase I/IIa study to evaluate the safety, tolerability and efficacy of a single topical dose of all … Ended
  2024-518757-42-00 9 2024-10-28 Difficult-to-heal venous leg ulcers
• A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy Ended
  2024-511998-30-00 5 2024-10-18 Narcolepsy with Cataplexy (Narcolepsy Type 1)
• An open-label, crossover trial in otherwise healthy volunteers with allergic rhinitis to evaluate the relative bioavailability and hemodynam … Ended
  2024-514037-38-00 3 2024-10-01 Anaphylaxis
• A single-centre, open-label, phase I trial evaluating the pharmacokinetics of single ascending oral doses of IRL757 in healthy elderly volun … Ended
  2024-515124-36-00 3 2024-09-24 Apathy in neurodegenerative disorders
• A study to test whether BI 1819479 improves lung function in people with idiopathic pulmonary fibrosis (IPF). Ended
  2023-508395-11-00 4 2024-09-10 idiopathic pulmonary fibrosis
• A study to test whether BI 1839100 improves cough in people with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis Ended
  2023-510249-79-00 4 2024-09-10 Progressive pulmonary fibrosis (PPF)
• A First-in-Human, randomised, double blind, placebo-controlled, single ascending dose trial to evaluate safety, tolerability, and pharmacoki … Ended
  2023-507939-38-00 1 2024-08-28 Urinary tract infections (UTIs)/complicated UTI (cUTI)
• A study to learn about how well a new drug called BAY3283142 works and how safe it is in reducing albumin in the urine of people with chroni … Ended
  2023-505755-40-00 4 2024-08-16 Chronic kidney disease
• A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED PHASE I TRIAL TO INVESTIGATE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING TO … Ended
  2024-512893-86-00 3 2024-08-06 Actinic keratosis
• A trial in healthy volunteers to study safety, tolerability, CS014-levels and effects in the body, after single and repeated doses of CS014, … Ended
  2024-510878-24-00 1 2024-06-24 Cardiovascular disease
• A prospective, single-centre, randomised, double-blind, placebo-controlled, phase I, First-In-Human (FIH) trial evaluating the safety and to … Ended
  2024-511426-31-00 1 2024-05-16 Apathy in neurodegenerative disorders
• The Attractive 2 trial – An open-label, randomised, 2-period cross-over trial to assess the pharmacokinetics of ATR-258 oral capsule vs. ora … Ended
  2023-508797-28-00 3 2024-04-24 Type 2 diabetes (T2D)
• Brain effects of hormonal contraceptives. Ended
  2023-507842-10-00 6 2024-03-18 Contraception
• A study to learn if baxdrostat works at reducing blood pressure and is safe in people with high blood pressure Ended
  2023-505499-32-00 5 2024-03-08 Uncontrolled hypertension (uTHN) defined as blood pressure that remain
• A24110He in a placebo-controlled trial evaluating safety in subjects with elevated plasma triglycerides Ended
  2023-509091-42-00 4 2024-02-27 Moderate to severe hypertriglyceridemia
• A phase 1, randomised, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study to evaluate the safety, tol … Ended
  2023-506912-41-00 3 2024-01-09 Idiopathic pulmonary fibrosis
• A randomised, placebo-controlled, double-blinded, cross-over, Phase 1 study evaluating the safety and preliminary efficacy of the GLP 1 anal … Ended
  2023-507758-34-00 3 2023-11-10 Overweight
• An open-label, healthy subject, two-part study to assess the effect of verapamil on systemic exposure of EP395 (Part A), and to assess the e … Ended
  2023-506345-34-00 3 2023-10-23 Chronic obstructive pulmonary disease (COPD)
• A study to compare how well gadoquatrane works and its safety with an already available contrast agent for MRI in people with known or suspe … Ended
  2022-501884-41-00 5 2023-09-29 Contrast enhancement in magnetic resonance imaging for assessment of c
• Control Of BioEquivalence with Xenical (COBEX): A Phase I, randomized, active-control study to evaluate EMP22 pharmacodynamics and EMP16 pha … Ended
  2023-505671-74-00 2 2023-09-22 Obesity
• A study to compare the effects and safety of gadoquatrane with an already used available contrast agent for MRI tests in people with any kno … Ended
  2022-501885-24-00 5 2023-09-20 Contrast enhancement in magnetic resonance imaging for assessment of n
• A trial to evaluate safety and characteristics of a substance for treatment of chronic hepatitis Ended
  2023-503880-40-00 4 2023-09-19 Chronic hepatitis B
• A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PARALLEL AND PLACEBO-CONTROLLED SINGLE AND MULTIPLE ASCENDING DOSE TRIAL INVESTIGATING SAFETY, TOLERAB … Ended
  2023-505280-36-00 1 2023-08-25 Erectile dysfunction
• A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants with Heart Failure and … Ended
  2022-502382-25-00 4 2023-08-24 Heart Failure and Pulmonary Hypertension due to Left Heart Disease (WH

Showing 289–312 of 354 trials